EPC-Mediated Tumor Delivery for Marker-Independent Cancer Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, such as chemotherapy, radiotherapy, and immunotherapy, suffer from lack of specificity, leading to significant side effects on normal tissues due to non-targeted delivery, and immunotherapies like CAR T-cells are limited by their reliance on specific antigen expression, making them ineffective across different cancer clones.

Innovation Solution

A delivery system using endothelial progenitor cells (EPCs) labeled with imaging or therapeutic agents, which are mobilized from bone marrow and specifically home to tumors, allowing targeted treatment and imaging independent of surface markers, enhanced by priming with cancer-derived media.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatments (chemotherapy, radiotherapy) are used, then cancer cells are killed, but normal tissues suffer significant side effects due to non-targeted delivery

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects on normal tissues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses endothelial progenitor cells (EPCs) as intermediary carriers that can be labeled with therapeutic or imaging agents. These EPCs serve as a mediator to deliver treatment specifically to tumor vessels, avoiding direct exposure of normal tissues to cytotoxic agents while maintaining treatment efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies local quality by targeting specific tumor vasculature through EPC homing. The EPCs accumulate preferentially in tumor tissues due to their unique vascular characteristics, allowing localized delivery of therapeutic agents to the tumor site while sparing normal tissues from treatment-related harm.

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If CAR T-cell immunotherapy is used, then tumor-specific targeting is achieved, but the therapy is limited by dependence on specific antigen expression, reducing effectiveness across different cancer clones

Engineering Contradiction:

Improveapplication across different cancersVSAvoidtumor targeting effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent achieves universality by utilizing EPCs as a delivery platform that can target various types of tumors across different cancer types. The EPCs homing mechanism is not dependent on specific tumor antigens but rather on the universal presence of abnormal angiogenesis and vascular permeability in tumors, enabling broad applicability across different cancer clones and types.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250222144A1Compositions and methods for targeted treatment and imaging of cancer tumors

Publication Date: 2025.07.10 WASHINGTON UNIV IN SAINT LOUIS

AI summary

Among the various aspects of the present disclosure is the provision of compositions and methods for targeted treatment and imaging of cancers or tumors.